Press Releases

Press Releases

 
Press Releases
Date Title and Summary View
Oct 25, 2016 SAN DIEGO, Oct. 25, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its third quarter 2016 financial results after the market closes on Thursday, November 3, 2016 followed by ...
Sep 13, 2016 SAN DIEGO, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today provided a corporate update. VTL-308 Enrollment Update ...
Aug 15, 2016 SAN DIEGO, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that Faheem Hasnain has been appointed to its Board of Directors, effective immediately.  In conjun...
Aug 2, 2016 SAN DIEGO, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the second quarter ended June 30, 2016....
Jul 21, 2016 SAN DIEGO, July 21, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its second quarter 2016 financial results after the market closes on Tuesday, August 2, 2016 followed by a ...
May 23, 2016 SAN DIEGO, May 23, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced the first subject was recently enrolled in its phase 3 trial designated VTL-308.  There are now ten ...
May 9, 2016 SAN DIEGO, May 09, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the first quarter ended March 31, 2016. ...
Apr 28, 2016 SAN DIEGO, April 28, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its first quarter 2016 financial results after the market closes on Monday, May 9, 2016. The press release will be followed by a confe...
Mar 8, 2016 SAN DIEGO, March 08, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the fourth quarter and full year ended December 31, 2015 and provided a corporate update. "Since the FDA's re...
Feb 24, 2016 SAN DIEGO, Feb. 24, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, will release its fourth quarter and full year 2015 financial results after the market closes on Tuesday, March 8, 2016. The press release ...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase